Molecular docking analysis of selected bioactive components of Glycyrrhiza glabra against bronchial asthma
DOI:
https://doi.org/10.47552/ijam.v14i2.3415Keywords:
Histamine 1 receptor, Prostaglandin H2 synthases, TNF alpha, IL6, COX1 and COX 2, Bronchial asthma, Athimathura choornamAbstract
Bronchial asthma is a chronic inflammatory disease of the lung by the combined action of various cytokines. As a result of the strong inflammatory response increased infiltration of cytokines result, damages respiratory epithelium, Hyperplasia of the trachealis muscle, and increased mucous production. Athimathura choornam is a promising drug used in all inflammatory conditions. Objective: To explore the efficacy of the Siddha formulation Athimathura choornam, an anti asthmatic drug using computational molecular docking analysis. Method: Based on the phytochemical study the active principles present in the plant Athimathuram were retrieved. 3D structure of the targets were retrieved from the repository and purified before the initiation of docking using the software. The potency of the drug was screened based on the binding of the ligands Asparagine, Liquiritin, and Glabridin with targets mentioned. These results were compared with the standard drugs such as Cetirizine, Salicylic acid, Diclofenac, Ibuprofen, and Celecoxib. Results and Conclusion: Liquiritin has 9 interactions (90%) similar to that of Ibuprofen, 14 interactions (90%) similar to that of Citrazinehence , 5 interactions (100%) similar to that of salicylic acid hence it has promising COX 1 inhibition ,Histamine 1 blocking activity and Prostaglandin Synthase inhibition activity. Asparagine has 3 interactions (60%) similar to Celecoxib, has promising COX 2 inhibition activity. Glabridin has 2 interactions (50%) similar to that of Diclofenac hence it has promising IL6 inhibition activity.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 International Journal of Ayurvedic Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author hereby transfers, assigns, or conveys all copyright ownership to the International Journal of Ayurvedic Medicine (IJAM). By this transfer, the article becomes the property of the IJAM and may not be published elsewhere without written permission from the IJAM.
This transfer of copyright also implies transfer of rights for printed, electronic, microfilm, and facsimile publication. No royalty or other monetary compensation will be received for transferring the copyright of the article to the IJAM.
The IJAM, in turn, grants each author the right to republish the article in any book for which he or she is the author or editor, without paying royalties to the IJAM, subject to the express conditions that (a) the author notify IJAM in advance in writing of this republication and (b) a credit line attributes the original publication to IJAM.